Background
Urothelial carcinoma (UC) is one of the most commonly diagnosed malignancies, with an estimated 80 thousand new cases and 18 thousand deaths in the United States in 2019 [
1]. UC is mainly composed of upper tract urothelial carcinoma (UTUC) and bladder cancer (BC), which are situated at the upper and lower urinary tract, respectively [
2]. UTUC is a rare disease that accounts for approximately 5–10% UC, while BC takes up 90–95% of UC and is the most common urinary tract malignancy [
3,
4]. Although radical nephroureterectomy (RUN) with bladder cuff excision is the standard treatment for patients with non-metastatic UTUC, high incidences of postoperative disease recurrence have been reported [
2,
5]. Radical cystectomy (RC) is the standard approach in patients with non-metastatic muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC), while the 5-year overall survival (OS) rate after RC is approximately 60% [
4,
6,
7].
Thus, it is important to precisely predict clinical course after surgery during counseling to determine the suitable treatment and follow-up strategies for individual patients with UC. Pathological T stage and tumor grade are established prognostic factors, besides several prognostic favors are also presented, including lymphovascular invasion, tumor necrosis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), systemic inflammation and others [
2,
4,
6‐
8].
Aminotransaminases, including aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT), are enzymes released from the liver cell into the blood stream, reflecting hepatocellular damage [
9]. The ratio of the serum activities of AST to ALT, firstly described by De Ritis and known as the De Ritis ratio [
10]. The De Ritis ratio has been used as a predictor of several chronic liver diseases [
11]. Recently, this ratio has been considered as a prognostic biomarker for various malignancies, such as renal cell carcinoma, pancreatic cancer, and breast cancer [
12‐
14]. While in patients with surgically treated UC, the prognostic value of De Ritis ratio is still unclear. Nishikawa et al. found that elevated De Ritis ratio is associated with recurrence-free survival (RFS) in patients with UC, while the other study did not detect the significant association between elevated De Ritis ratio and RFS [
15,
16]. As a result, we conducted this systematic review and meta-analysis to explore the prognostic value of preoperative De Ritis ratio in patients after surgery for UC.
Method
Literature search strategy
Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement, we conducted this systematic review and meta-analysis. We searched the PubMed, Embase, the Cochrane library up to October 2019. We applied the following items: urothelial carcinoma (urothelial, bladder, tumor, cancer or carcinoma) and De Ritis ratio (aspartate aminotransferase, AST, alanine aminotransferase, ALT, AST/ALT ratio, AST to ALT ratio) as keywords or Mesh. We also screened the reference lists of all eligible studies to ensure comprehensive search. Two reviewers screened the literature independently, any disagreements were resolved by discussing or consulting another one.
Inclusion and exclusion criteria
We included articles conforming to the following inclusion criteria: (1) random-controlled studies or observational studies; (2) patients were diagnosed urothelial carcinoma and underwent surgery; (3) De Ritis ratio was obtained before surgery; (4) evaluated the prognostic value of preoperative De Ritis ratio, (5) reported available data for analyses, for example: overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), progression-free survival (PFS) or metastasis-free survival (MFS). The following studies were excluded: (1) non-English language; (2) patients did not undergo surgery; (3) did not involve the De Ritis ratio, (4) no available data for analyses. We did not include conference abstracts owing to incomplete information. Regarding duplicated records, we only included the most recent and informative study.
Data extraction and quality assessment
Two reviewers extracted items from all eligible studies independently, which are as follows: the name of the first author and published year, enrollment data and location, study type, diseases, intervention, number of patients, age, the cutoff value of the De Ritis ratio, the duration of follow-up. Concerning the clinical outcome such as OS, CSS, RFS, and PFS, we extracted hazard ratio (HR) and 95% confidence interval (CI) from the studies. If the HRs and 95% CI were not revealed, we could calculate the HR and 95% CI based on the method by Tierney [
17]. We used the Newcastle–Ottawa Quality Assessment Scale (NOS) to evaluate the quality of the observational studies. And studies with a score of no less than 7 were considered as good quality.
Statistical analysis
We conducted all statistical analyses by using STATA version 12 (StataCorp, College Station, TX, USA). As for the clinical outcome, we pooled the HRs and 95% CI. And we used Q and I
2 statistics to evaluate the heterogeneity among studies. A random-effect model was used when we observed the significant heterogeneity (P < 0.10 or I
2 > 50%); otherwise, a fixed-effect model was used [
18]. We also carried out subgroup analyses based on available data. In addition, we performed sensitivity analyses to test the robustness of the final results. In terms of the publication bias, we used Egger’s test and Begg’s test. A two-sided P-value < 0.05 was considered as a statistical difference.
Discussion
Despite the development of surgical techniques and adjuvant therapies, the prognosis of patients with UC did not improve a lot. Several prognostic factors were proposed in recent years, including lymphovascular invasion, tumor necrosis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), systemic inflammation and others [
2,
4,
6‐
8].
In this study, we evaluated the prognostic value of De Ritis ratio in patients with surgically treated UC. We demonstrated that a higher preoperative De Ritis ratio is associated with inferior OS, CSS, PFS, and RFS. When stratified by diseases, the elevated preoperative De Ritis ratio was also an unfavorable factor in patients with either BC or UTUC. Regarding the difference of cutoff values, we divided studies into ≤ 1.3 and > 1.3 groups and found that elevated De Ritis ratio is correlated to poor OS and CSS. In addition, we conducted sensitivity analyses and did not observe a relatively big change. There was also no evidence for publication bias, reflecting the robustness of our results.
So far, several studies have shown the prognostic value of aminotransaminases in patients with malignancies irrespective of the presence of liver-specific disease [
12‐
14,
25,
26]. For example, Stocken et al. found that AST was associated with overall survival in patients with pancreatic cancer [
13]. Generally, AST is widely expressed in various tissues such as the brain, muscle, kidney, but ALT is regarded as more liver-specific or enriched [
11]. Pathological processes were shown to bring about tissue damage and higher proliferative status, and high tumor cell turnover tends to increase AST rather than ALT, making the De Ritis ratio an attractive potential biomarker [
27].
De Ritis ratio, the ratio of the serum activities of AST to ALT, was firstly described by De Ritis [
10]. The De Ritis ratio was mostly used as a predictor of several chronic liver diseases in previous studies [
11]. Currently, several studies have demonstrated that the De Ritis ratio could serve as a prognostic factor in patients with several cancers. For instance, Bezan et al. enrolled 698 patients with nonmetastatic renal cell carcinoma and found that increased (≥ 1.26) preoperative AST/ALT ratio was an independent prognostic factor for metastasis-free survival (HR 1.61, 95% CI 1.25–2.07, P < 0.001) and OS (HR 1.76, 95% CI 1.34–2.32, P < 0.001). Furthermore, Lee et al. revealed that elevated AST/ALT ratio was an unfavorable factor for OS, CSS, and PFS in patients surgically treated for localized clear-cell RCC [
28]. We summarized all available studies and also found that elevated De Ritis ratio is associated with poor prognosis in patients after surgery for urothelial carcinoma.
The association between the De Ritis ratio and histological tumor necrosis, pathological T stage strength this finding. Currently, tumor metabolism has gained attention concerning the carcinogenesis of malignancies. The Warburg effect is the well-known cancer metabolism, describing the abnormal anaerobic glycolysis in cancer cells for producing adenosine triphosphate (ATP) regardless of the availability of the oxygen [
29]. Increased glycolysis is shown to be associated with mitochondrial dysfunction linked to nicotinamide adenine dinucleotide (NAD)-related enzymes and glucose transporters [
30]. Furthermore, AST is a component of a malate-aspartate shuttle pathway that allows NADH/NAD
+ conversion [
31]. Therefore, the De Ritis ratio might be related to tumor metabolism in many glucose-using cancers. Reportedly, urothelial carcinoma was associated with glucose metabolism [
32]. Whyard et al. researched the uptake of fluorescent glucose by bladder cancer cells using fluorescence microscopy and observed significant differences in glucose consumption between normal urothelium and malignant urothelial cells [
33]. Based on these findings and our study, it is highly likely that the De Ritis ratio is associated with the prognosis of patients with urothelial carcinoma. But the detailed interaction between the De Ritis ratio and poor prognosis of patients with urothelial carcinoma remains to be explored.
The De Ritis ratio has important implications for clinical practice. The patients with a higher De Ritis ratio had an inferior survival. It may serve as a potential selection criterion for risk factor stratified management of urothelial carcinoma and adjuvant therapies. Besides, close postoperative follow-up should be emphasized for these patients. The AST/ALT ratio is easily accessible and relatively inexpensive because AST and ALT are the most commonly used serum biomarkers in our daily clinical practice.
Despite our novel findings, the present study has some limitations. Firstly, a total of 8 studies incorporating 3949 patients was included in the quantitative synthesis, which is a relatively small number and may limit the power of the final results. So more studies are needed to validate our findings. Secondly, all studies are retrospective, which may increase the risk of bias because of the retrospective data analysis. Thirdly, although included studies tried to exclude all patients with acute or chronic liver disease, they may not eliminate the undetected diseases that confounded results. As results, the De Ritis ratio must be validated in large, independent cohorts before it can be applied widely.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.